205 related articles for article (PubMed ID: 31984451)
21. Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.
Hantel C; Jung S; Mussack T; Reincke M; Beuschlein F
Endocr Relat Cancer; 2014 Jun; 21(3):383-94. PubMed ID: 24532475
[TBL] [Abstract][Full Text] [Related]
22. Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial.
Kroiss M; Quinkler M; Johanssen S; van Erp NP; Lankheet N; Pöllinger A; Laubner K; Strasburger CJ; Hahner S; Müller HH; Allolio B; Fassnacht M
J Clin Endocrinol Metab; 2012 Oct; 97(10):3495-503. PubMed ID: 22837187
[TBL] [Abstract][Full Text] [Related]
23. Targeting 11-Beta Hydroxylase With [131I]IMAZA: A Novel Approach for the Treatment of Advanced Adrenocortical Carcinoma.
Hahner S; Hartrampf PE; Mihatsch PW; Nauerz M; Heinze B; Hänscheid H; Teresa Fuß C; Werner RA; Pamporaki C; Kroiss M; Fassnacht M; Buck AK; Schirbel A
J Clin Endocrinol Metab; 2022 Mar; 107(4):e1348-e1355. PubMed ID: 34904171
[TBL] [Abstract][Full Text] [Related]
24. Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib.
Kroiss M; Megerle F; Kurlbaum M; Zimmermann S; Wendler J; Jimenez C; Lapa C; Quinkler M; Scherf-Clavel O; Habra MA; Fassnacht M
J Clin Endocrinol Metab; 2020 May; 105(5):1461-8. PubMed ID: 31900481
[TBL] [Abstract][Full Text] [Related]
25. A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors.
Mehnert JM; Edelman G; Stein M; Camisa H; Lager J; Dedieu JF; Ghuysen AF; Sharma J; Liu L; LoRusso PM
Invest New Drugs; 2018 Feb; 36(1):36-44. PubMed ID: 28417284
[TBL] [Abstract][Full Text] [Related]
26. Risk of adrenocortical carcinoma in adrenal tumours greater than 8 cm.
Abdel-Aziz TE; Rajeev P; Sadler G; Weaver A; Mihai R
World J Surg; 2015 May; 39(5):1268-73. PubMed ID: 25526921
[TBL] [Abstract][Full Text] [Related]
27. Survivin in adrenocortical tumors - pathophysiological implications and therapeutic potential.
Sbiera S; Kroiss M; Thamm T; Beyer M; Majidi F; Kuehner D; Wobser M; Becker JC; Adam P; Ronchi C; Allolio B; Fassnacht M
Horm Metab Res; 2013 Feb; 45(2):137-46. PubMed ID: 23143666
[TBL] [Abstract][Full Text] [Related]
28. High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up.
Mauclère-Denost S; Leboulleux S; Borget I; Paci A; Young J; Al Ghuzlan A; Deandreis D; Drouard L; Tabarin A; Chanson P; Schlumberger M; Baudin E
Eur J Endocrinol; 2012 Feb; 166(2):261-8. PubMed ID: 22048971
[TBL] [Abstract][Full Text] [Related]
29. In vitro cytotoxicity of cabazitaxel in adrenocortical carcinoma cell lines and human adrenocortical carcinoma primary cell cultures
Fragni M; Palma Lopez LP; Rossini E; Abate A; Cosentini D; Salvi V; Vezzoli S; Poliani PL; Bosisio D; Hantel C; Tiberio GAM; Grisanti S; Memo M; Terzolo M; Berruti A; Sigala S
Mol Cell Endocrinol; 2019 Dec; 498():110585. PubMed ID: 31536779
[TBL] [Abstract][Full Text] [Related]
30. Rapid and Complete Remission of Metastatic Adrenocortical Carcinoma Persisting 10 Years After Treatment With Mitotane Monotherapy: Case Report and Review of the Literature.
El Ghorayeb N; Rondeau G; Latour M; Cohade C; Olney H; Lacroix A; Perrotte P; Sabourin A; Mazzuco TL; Bourdeau I
Medicine (Baltimore); 2016 Mar; 95(13):e3180. PubMed ID: 27043680
[TBL] [Abstract][Full Text] [Related]
31. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma.
Haluska P; Worden F; Olmos D; Yin D; Schteingart D; Batzel GN; Paccagnella ML; de Bono JS; Gualberto A; Hammer GD
Cancer Chemother Pharmacol; 2010 Mar; 65(4):765-73. PubMed ID: 19649631
[TBL] [Abstract][Full Text] [Related]
32. New perspectives for mitotane treatment of adrenocortical carcinoma.
Puglisi S; Calabrese A; Basile V; Pia A; Reimondo G; Perotti P; Terzolo M
Best Pract Res Clin Endocrinol Metab; 2020 May; 34(3):101415. PubMed ID: 32179008
[TBL] [Abstract][Full Text] [Related]
33. Salvage Treatment of Adrenocortical Carcinoma with Trofosfamide.
Kroiss M; Deutschbein T; Schlötelburg W; Ronchi CL; Neu B; Müller HH; Quinkler M; Hahner S; Heidemeier A; Fassnacht M;
Horm Cancer; 2016 Jun; 7(3):211-8. PubMed ID: 26961793
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma.
Laganà M; Grisanti S; Ambrosini R; Cosentini D; Abate A; Zamparini M; Ferrari VD; Gianoncelli A; Turla A; Canu L; Terzolo M; Tiberio GAM; Sigala S; Berruti A
ESMO Open; 2022 Apr; 7(2):100422. PubMed ID: 35272132
[TBL] [Abstract][Full Text] [Related]
35. Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression.
Zancanella P; Pianovski MA; Oliveira BH; Ferman S; Piovezan GC; Lichtvan LL; Voss SZ; Stinghen ST; Callefe LG; Parise GA; Santana MH; Figueiredo BC
J Pediatr Hematol Oncol; 2006 Aug; 28(8):513-24. PubMed ID: 16912591
[TBL] [Abstract][Full Text] [Related]
36. ATR-101 disrupts mitochondrial functions in adrenocortical carcinoma cells and in vivo.
Cheng Y; Kerppola RE; Kerppola TK
Endocr Relat Cancer; 2016 Apr; 23(4):1-19. PubMed ID: 26843528
[TBL] [Abstract][Full Text] [Related]
37. Management of Adrenocortical Carcinoma.
Jasim S; Habra MA
Curr Oncol Rep; 2019 Feb; 21(3):20. PubMed ID: 30798468
[TBL] [Abstract][Full Text] [Related]
38. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement.
Chortis V; Taylor AE; Schneider P; Tomlinson JW; Hughes BA; O'Neil DM; Libé R; Allolio B; Bertagna X; Bertherat J; Beuschlein F; Fassnacht M; Karavitaki N; Mannelli M; Mantero F; Opocher G; Porfiri E; Quinkler M; Sherlock M; Terzolo M; Nightingale P; Shackleton CH; Stewart PM; Hahner S; Arlt W
J Clin Endocrinol Metab; 2013 Jan; 98(1):161-71. PubMed ID: 23162091
[TBL] [Abstract][Full Text] [Related]
39. A Micellar Mitotane Formulation with High Drug-Loading and Solubility: Physico-Chemical Characterization and Cytotoxicity Studies in 2D and 3D In Vitro Tumor Models.
Haider MS; Schreiner J; Kendl S; Kroiss M; Luxenhofer R
Macromol Biosci; 2020 Jan; 20(1):e1900178. PubMed ID: 31596553
[TBL] [Abstract][Full Text] [Related]
40. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors.
Fassnacht M; Dekkers OM; Else T; Baudin E; Berruti A; de Krijger R; Haak HR; Mihai R; Assie G; Terzolo M
Eur J Endocrinol; 2018 Oct; 179(4):G1-G46. PubMed ID: 30299884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]